List view / Grid view

News

Lapatinib and trastuzumab shrinks HER2+ breast cancers within 11 days

11 March 2016 | By Victoria White

A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.…

Brussels Declaration on ADPKD one year on

10 March 2016 | By Victoria White

EAF experts have issued a collaborative letter to over 350 European decision makers celebrating the year one progress of the Brussels Declaration on ADPKD...

Aprea closes EUR 46 million Series B financing round

9 March 2016 | By Victoria White

Aprea says the funds will be used to advance the clinical development of its lead programme APR-246, a first-in-class anticancer compound reactivating the tumour suppressor protein p53...